Endologix Upgraded to Buy by BTIG Research (ELGX)
Endologix (NASDAQ:ELGX) was upgraded by research analysts at BTIG Research from a “neutral” rating to a “buy” rating in a report released on Monday, TheFlyOnTheWall.com reports. The firm currently has a $17.00 price target on the stock. BTIG Research’s price objective suggests a potential upside of 27.92% from the stock’s previous close.
Several other analysts have also recently commented on the stock. Analysts at JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Endologix in a research note on Thursday, July 31st. They now have a $17.00 price target on the stock, up previously from $15.00. Separately, analysts at Credit Suisse initiated coverage on shares of Endologix in a research note on Tuesday, July 29th. They set an “outperform” rating on the stock. Finally, analysts at Credit Suisse initiated coverage on shares of Endologix in a research note on Monday, June 30th. They set an “outperform” rating and a $19.00 price target on the stock. One analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the stock. Endologix currently has a consensus rating of “Buy” and an average price target of $17.75.
Shares of Endologix (NASDAQ:ELGX) opened at 13.29 on Monday. Endologix has a 52 week low of $11.47 and a 52 week high of $18.85. The stock’s 50-day moving average is $14.06 and its 200-day moving average is $13.96. The company’s market cap is $889.8 million.
Endologix (NASDAQ:ELGX) last posted its quarterly earnings results on Wednesday, July 30th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.02. The company had revenue of $38.30 million for the quarter, compared to the consensus estimate of $36.50 million. During the same quarter in the previous year, the company posted ($0.03) earnings per share. The company’s revenue for the quarter was up 12.6% on a year-over-year basis. On average, analysts predict that Endologix will post $-0.28 earnings per share for the current fiscal year.
Endologix, Inc (NASDAQ:ELGX) is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.